Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review

Value in Health

Volumn 19, Issue 2, 2016, Pages 267-276

  Koufopoulou, Maria ^a   Sutton, Andrew John ^a   Breheny, Katie ^a   Diwakar, Lavanya ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

economic evaluations; interferon gamma release assays; screening; systematic review; tuberculin skin tests; tuberculosis

Indexed keywords

CHECKLIST; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SCREENING TEST; SYSTEMATIC REVIEW; TUBERCULIN TEST; VALIDITY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE COST; IMMUNOLOGY; MICROBIOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TUBERCULIN TEST;

EID: 84953293058     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.11.006     Document Type: Review

References (49)

1. Global Tuberculosis Report 2014. World Health Organization, Geneva, Switzerland.
2. M.D. Nettleman, H. Geerdes, and M.C. Roy The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine Arch Intern Med 157 1997 1121 1127
3. J. Dinnes, J. Deeks, H. Kunst, and et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection Health Technol Assess 11 2007 1 196
4. M. Bocchino, A. Matarese, and A. Sanduzzi Current treatment options for latent tuberculosis infection J Rheumatol 91 2014 71 77
5. Centers for Disease and Control Prevention. Latent tuberculosis infection: a guide for primary care providers. Available from: http://www.cdc.gov/tb/publications/ltbi/diagnosis.htm. [Accessed December 24, 2015].
6. D. Menzies, M. Pai, and G. Comstock Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research Ann Intern Med 146 2007 340 354
7. A. Ayub, S.H. Yale, K.D. Reed, and et al. Testing for latent tuberculosis Clin Med Res 2 2004 191 194
8. I.O. Al-Orainey Diagnosis of latent tuberculosis: can we do better? Ann Thorac Med 4 2009 5 9
9. S. Moradmand, and M. Rasoolinejad What is the optimal test for diagnosis of latent tuberculosis? Acta Med Iran 50 2012 361 362
10. S. Polinder, M. Segui-Gomez, H. Toet, and et al. Systematic review and quality assessment of economic evaluation studies of injury prevention Accid Anal Prev 45 2012 211 221
11. M.F. Drummond, M.J. Sculpher, G.W. Torrance, and et al. Methods for the Economic Evaluation of Health Care Programmes 3rd ed. 2005 Oxford University Press Oxford
12. P. Barton, S. Bryan, and S. Robinson Modelling in the economic evaluation of health care: selecting the appropriate approach J Health Serv Res Policy 9 2004 110 118
13. A.K. Lugner, S.D. Mylius, and J. Wallinga Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic Health Econ 19 2010 518 531
14. A. Liberati, D.G. Altman, J. Tetzlaff, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
15. M.F. Drummond, and T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 1996 275 283
16. J.G. Gonzalez-Perez Developing a scoring system to quality assess economic evaluations Eur J Health Econ 3 2002 131 136
17. M.A. de Perio, J. Tsevat, G.A. Roselle, and et al. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers Arch Intern Med 169 2009 179 187
18. M.T. del Campo, H. Fouad, M.M. Solis-Bravo, and et al. Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers Infect Control Hosp Epidemiol 33 2012 1226 1234
19. S. Deuffic-Burban, K. Atsou, N. Viget, and et al. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection Int J Tuberc Lung Dis 14 2010 471 481
20. R. Diel, A. Nienhaus, C. Lange, and T. Schaberg Cost-optimisation of screening for latent tuberculosis in close contacts Eur Respir J 28 2006 35 44
21. R. Diel, A. Nienhaus, and R. Loddenkemper Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany Chest 131 2007 1424 1434
22. R. Diel, P. Wrighton-Smith, and J.P. Zellweger Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis Eur Respir J 30 2007 321 332
23. R. Diel, T. Schaberg, R. Loddenkemper, and et al. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany Respir Med 103 2009 1838 1853
24. A.B. Hardy, R. Varma, T. Collyns, and et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries Thorax 65 2010 178 180
25. A.Z. Iqbal, J. Leighton, J. Anthony, and et al. Cost-effectiveness of using Quantiferon Gold (QFT-G) (R) versus tuberculin skin test (TST) among U.S. and foreign born populations at a public health department clinic with a low prevalence of tuberculosis Public Health Nurs 31 2014 144 152
26. A. Kowada, O. Takahashi, T. Shimbo, and et al. Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan Mol Diagn Ther 12 2008 235 251
27. A. Kowada Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy Mol Diagn Ther 14 2010 367 373
28. A. Kowada Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening Mol Diagn Ther 16 2012 181 190
29. A. Kowada Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons Epidemiol Infect 141 2013 2224 2234
30. A. Kowada Cost effectiveness of the interferon-gamma release assay for tuberculosis screening of hemodialysis patients Nephrol Dial Transplant 28 2013 682 688
31. A. Kowada Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries J Infect 68 2014 32 42
32. A. Kowada, J. Takasaki, and N. Kobayashi Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries J Hosp Infect 89 2015 99 108
33. A. Kowada Cost-effectiveness of tobacco cessation support combined with tuberculosis screening among contacts who smoke Int J Tuberc Lung Dis 19 2015 857 863
34. B.L. Laskin, J. Goebel, J.R. Starke, and et al. Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children Am J Kidney Dis 61 2013 22 32
35. B.P. Linas, A.Y. Wong, K.A. Freedberg, and C.R. Horsburgh Jr Priorities for screening and treatment of latent tuberculosis infection in the United States Am J Respir Crit Care Med 184 2011 590 601
36. J.D. Mancuso, D.W. Niebuhr, K.D. Frick, and et al. Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis Int J Tuberc Lung Dis 15 2011 1223 1230
37. A.M. Mandalakas, A.C. Hesseling, R.P. Gie, and et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting Thorax 68 2013 247 255
38. F. Marra, C.A. Marra, M. Sadatsafavi, and et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts Int J Tuberc Lung Dis 12 2008 1414 1424
39. O. Oxlade, K. Schwartzman, and D. Menzies Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis Int J Tuberc Lung Dis 11 2007 16 26
40. M. Pareek, M. Bond, J. Shorey, and et al. Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: observational study and economic analysis Thorax 68 2013 230 239
41. A. Pooran, H. Booth, R.F. Miller, and et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis BMC Pulm Med 10 2010 7
42. M. Shah, D. DiPietro, A. Greenbaum, and et al. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic PLoS One 7 2012 e36551
43. R.E. Steffen, R. Caetano, M. Pinto, and et al. Cost-effectiveness of Quantiferon(R)-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil PLoS One 8 2013 e59546
44. A. Swaminath, N. Bhadelia, and Y.C. Wang Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease Inflamm Bowel Dis 19 2013 2444 2449
45. M. Pai, A. Zwerling, and D. Menzies Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update Ann Intern Med 149 2008 177 184
46. R. Diel, R. Loddenkemper, and A. Nienhaus Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis Chest 137 2010 952 968
47. M. Santin, L. Munoz, and D. Rigau Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis PLoS One 7 2012 e32482
48. M. Farhat, C. Greenaway, M. Pai, and D. Menzies False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10 2006 1192 1204
49. Z. Philips, L. Ginnelly, M. Sculpher, and et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment Health Technol Assess 8 2004 iii-xi, 1